





## Molecular and functional characterization of NF1 locus recurrent deletions

Hortense Guillaume dit Taunière<sup>1</sup>, Djihad Hadjadj, <sup>1</sup> Eric Pasmant<sup>1</sup>

<sup>1</sup> Institut Cochin, Inserm U1016 - CNRS UMR8104 - Université Paris Cité, CARPEM, Paris, France



**Neurofibromatosis type 1** (NF1) is caused by **loss-of-function** 



To analyze precisely the **molecular mechanisms** of non-allelic homologous recombination (NAHR) between repeated sequences located at 17q11.2 using a long-read sequencing **approach** (Oxford Nanopore Technologies, ONT).

variants in the NF1 gene (17q11.2), among which 5-10% are **deletions** of the whole *NF1* locus. These deletions are associated with a severe clinical presentation in NF1 patients<sup>1</sup> (Figure 1).



To study if the **blood methylome** of NF1 patients with large 17q11.2 locus deletions differs from that of NF1 patients with intragenic mutations. This **episignature** could include elements identified in (i) episignatures linked to syndromes caused by constitutional heterozygous loss-of-function mutations of PRC2 members (for SUZ12: Imagawa-Matsumoto syndrome, for EZH2: Weaver syndrome and for EED: Cohen-Gibson syndrome) and (ii) methylomes of tumours with somatic bi-allelic loss of-function mutations of PRC2 (Figure 3).





**Figure 1.** Radar chart of the frequency of the NF1 main symptoms in the French *NF1*-deleted cohort and in "classic" NF1 (adapted from Pacot et al., *Cancers* 2021).

Three recurrent types of deletions have been described this far. They are caused by **non-allelic homologous recombination** (NAHR) mediated by low-copy repeats (LCR) at the NF1 locus (namely, NF1-*REPa, NF1-REPb,* and *NF1-REPc*), or by NAHR events between *SUZ12* and its pseudogene, SUZ12P<sup>2</sup> (Figure 2).



**Figure 2.** Illustration of the genomic region harboring the *NF1* and adjacent genes.

## **MATERIALS & METHODS**

- The team has recently implemented the innovative **nanopore** approach (ONT) for genomic rearrangements and methylome analysis, using an adaptive sequencing function to enrich ontarget reads through real-time alignment.
- A total of **121 index cases** with an **NF1 deletion** have been included. All patients were phenotypically described and had an (multiplex ligation-dependent probe amplification) MLPA genotyping of the three recurrent deletion types.

## CONCLUSION

- A comprehensive description of the repeated sequences located at the 17q11.2 locus could significantly improve our understanding of the specific NAHR mechanisms leading to NF1 locus recurrent deletions.
- The description of episignatures associated with these large deletions could reveal functional consequences and specifically implicate some of the deleted genes in the phenotype specifically associated with these deletions.
- Given the specific phenotype, it is important to finely characterize these rearrangements at the molecular level to allow more precise and specific genetic counseling in patients with large NF1 deletions in the future.

*References:* 

<sup>1</sup> Pacot *et al.*, Severe Phenotype in Patients with Large Deletions of *NF1*. *Cancers* 2021

<sup>2</sup> Kehrer-Sawatzki & Cooper. Classification of NF1 microdeletions and its importance for establishing genotype/phenotype correlations in patients with NF1 microdeletions. Hum Genet 2021

<sup>3</sup> Cyrus et al., Rare SUZ12 variants commonly cause an overg. Am J Med Genet C Semin Med Genet 2019